Lyell Immunopharma, Inc. (LYEL) Stock Overview
Explore Lyell Immunopharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Lyell Immunopharma, Inc. (LYEL)
Key Financials
Key Financials
Market Cap
267.8M
P/E Ratio
-0.68
EPS (TTM)
$-12.83
ROE
-0.92%
LYEL Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Lyell Immunopharma, Inc. (NASDAQ: LYEL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Lyell Immunopharma, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of LYEL on the NASDAQ shows an RSI of 30.60, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $28.64 for the NASDAQ listing.
Key metrics behind Lyell Immunopharma, Inc.'s NASDAQ-traded stock include a P/E ratio of -0.68 and a market capitalization of 267.8M. Combined with our AI analysis, these give both institutional and retail investors a clear view of LYEL on the NASDAQ.